Is brigatinib an imported drug or a domestic drug?

Brigatinib (Brigatinib) is an imported drug originally developed by Ariad Pharmaceuticals and now owned by Takeda Pharmaceuticals. Internationally, Brigatinib (Brigatinib) was first approved by the U.S. Food and Drug Administration (FDA) in 2017 for the treatment of crizotinib (Crizotinib) to treat patients with drug-resistant ALK-positive non-small cell lung cancer (NSCLC).

Brigatinib is currently on the market in China and has been included in the National Reimbursement Directory, allowing patients to obtain treatment at a more affordable price. Specifically, the domestic price of brigatinib is about four to five thousand yuan. For the specific price and medical insurance reimbursement ratio, patients need to consult the local hospital pharmacy. The inclusion of medical insurance has significantly reduced the financial burden on patients and improved the accessibility of drugs.

Although the price of brigatinib in China is relatively low, but it is still high compared with foreign generic drugs. Generic drugs of brigatinib produced abroad, especially in some developing countries such as Laos, are cheaper, usually only a few hundred yuan. These generic drugs are basically the same as the original drugs in terms of ingredients and efficacy, providing a more economical choice for some patients with limited financial conditions.

Currently in the Chinese market,Brigatinib is only sold as an imported original drug, and there is no domestic version yet. This means that Chinese patients can only purchase imported drugs when choosing treatment with brigatinib. Although its price has been reduced through medical insurance reimbursement, there is still a certain gap compared with foreign generic drugs. Therefore, qualified patients may choose to purchase generic drugs from abroad to further save treatment costs.

In summary,Brigatinib (Brigatinib) as an important second-generation ALK inhibitor, has been marketed in China and included in medical insurance, and is the most common ALKpositive in ChinaNSCLCEffective treatment options are available for patients. However, since only imported original drugs are sold in the domestic market and the prices are relatively high, some patients may choose to purchase foreign generic drugs to save costs. In the future, as more drugs are launched and competition intensifies, the domestic price of brigatinib is expected to drop further, further reducing the financial burden on patients.